Search Results

Press Releases

SOFIE Biosciences Announces First Patient Dosed in [18F]FAPI-74 Phase 3 Study

December 29, 2025

·

5 min read

Press Releases

NEURELIS TO PARTICIPATE IN SOFIE’S JOURNEY EPILEPSY AWARENESS DAY AND EDUCATION EXPO AT DISNEYLAND® RESORT

November 11, 2025

·

7 min read

Press Releases

SOFIE Biosciences Prepares Launch of Two [18F]FAPI-74 Phase 3 Studies, following successful FDA engagement

October 2, 2025

·

6 min read

Genetown

Life Molecular Imaging and SOFIE announce Neuraceq® availability in Cleveland

Life Molecular Imaging and SOFIE Biosciences, a national US manufacturer and developer of PET radiopharmaceuticals, announce that the companies have expanded their strategic partnership and licensing agreement to provide and distribute Neuraceq® out of SOFIE’s radiopharmaceutical manufacturing site located in Cleveland, Ohio.

April 5, 2024

·

5 min read

Press Releases

Life Molecular Imaging and SOFIE announce Neuraceq® availability in Somerset, NJ

January 7, 2025

·

6 min read

Business

RLS and Sofie Enter Strategic Partnership for Distribution of Nuclear Medicine Doses for Patients

RLS, Inc., the third-largest nuclear medicine pharmacy network in the US, and SOFIE Biosciences, a national US manufacturer and developer of PET radiopharmaceuticals, entered into a strategic partnership for RLS to distribute SOFIE nuclear medicine doses for patients.

June 21, 2023

·

2 min read

Drug Development

First Patient Imaged in SOFIE’s 18F-FAPI Phase 2 trial

SOFIE Biosciences (SOFIE), an established US manufacturer and developer of radiopharmaceuticals, has dosed and imaged the first patient with [18F]FAPI-74 in its US Clinical Trial of flourine-18 labeled Fibroblast Activation Protein Inhibitor (FAPI).

May 12, 2023

·

2 min read

Biotech Beach

NEURELIS TO PARTICIPATE IN 11th ANNUAL SOFIE’S JOURNEY EPILEPSY AWARENESS DAY AND EDUCATION EXPO AT DISNEYLAND® RESORT

Neurelis Inc., is proud to take part in the 11th Annual Sofie’s Journey Epilepsy Awareness Day and Education Expo at Disneyland Resort (EADDL), the largest, worldwide epilepsy community gathering of the year.

October 30, 2023

·

9 min read

Drug Development

SOFIE granted IND for 18F-FAPI in Phase 2 study

SOFIE Biosciences (SOFIE), an established US manufacturer and developer of radiopharmaceuticals, has received Investigational New Drug (IND) clearance to proceed with clinical study of [18F]FAPI-74, its lead fluorine-18 labelled Fibroblast Activation Protein Inhibitor (FAPI) product.

November 29, 2022

·

2 min read

Drug Development

First Patient Imaged in SOFIE’s FAPI Phase II trial

SOFIE Biosciences (SOFIE), an established US manufacturer and developer of radiopharmaceuticals, has dosed and imaged the first patient with [ 68 Ga]FAPI-46 at NYU Langone in its US Clinical Trial of Fibroblast Activation Protein Inhibitor (FAPI).

October 13, 2022

·

3 min read